As prescription drug abuse in the United States escalates, diversion of controlled substances is becoming an increasingly critical issue for hospitals and health system executives to monitor. In hospitals, diversion of controlled substances not only negatively impacts staff and places liability on the facility but it also affects patient safety, satisfaction, and in most cases, the hospital’s bottom line. As such, hospital executives are looking to pharmacy leaders to provide creative solutions to proactively prevent diversion and better control this evolving public health issue.
Paracetamol did not improve recovery time for people with low back pain, compared to placebo, according to a study published in The Lancet.
While there are signs of progress in the epidemic of prescription drug misuse, everyone is at risk of misuse, according to a new study.
FDA approved idelalisib (Zydelig, Gilead Sciences) to treat patients with 3 types of blood cancers.
The AbbVie purchase of Shire for about $54 billion will create one of the biggest deals so far this year.